GeneReach Biotechnology (4171) — Capital Reinvestment Ratio
GeneReach Biotechnology (4171) has a Capital Reinvestment Ratio of 1.29x as of June 2026, meaning it reinvests 1% of its operating cash flow (NT$6.28 Million) in capital expenditures (NT$8.13 Million). Check how tangible is GeneReach Biotechnology's equity to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
GeneReach Biotechnology Capital Reinvestment Ratio (2018–2022)
This chart tracks GeneReach Biotechnology's Capital Reinvestment Ratio across 4 annual periods. For the full cash flow conversion analysis, see cash efficiency ratio of GeneReach Biotechnology.
Annual Capital Reinvestment Ratio for GeneReach Biotechnology (2018–2022)
Year-by-year Capital Reinvestment Ratio for GeneReach Biotechnology from 2018 to 2022. See cash generation quality of GeneReach Biotechnology to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (TWD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2022 | 0.13x | NT$357.63 Million | NT$44.90 Million | ▲ +177.5% |
| 2021 | 0.05x | NT$348.99 Million | NT$15.79 Million | ▼ -88.2% |
| 2020 | 0.38x | NT$169.82 Million | NT$64.87 Million | ▼ -4.9% |
| 2018 | 0.40x | NT$5.74 Million | NT$2.31 Million | — |